New insider activity at Cel-Sci ( (CVM) ) has taken place on July 29, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Robert Eugene Watson has made a significant investment in Cel-Sci by purchasing 2,919 shares of the company’s stock, valued at $19,995.
Recent Updates on CVM stock
In the last 24 hours, Cel-Sci Corporation experienced significant trading activity, including multiple halts and resumptions. The trading halts were attributed to volatility and pending news, which were later clarified with the announcement of a $5.7 million at-the-market common stock offering. This offering aims to fund the continued development of their Multikine product, general corporate purposes, and working capital. Additionally, Cel-Sci announced a partnership with a Saudi Arabian pharmaceutical and healthcare company to further develop Multikine. These developments have likely influenced market perceptions and trading activity surrounding Cel-Sci’s stock.
Spark’s Take on CVM Stock
According to Spark, TipRanks’ AI Analyst, CVM is a Underperform.
Cel-Sci’s stock is significantly impacted by poor financial performance, with persistent losses and negative cash flows being major concerns. Technical analysis shows some positive momentum but is offset by the stock trading below key moving averages. The valuation is challenging due to ongoing losses, making the stock less attractive for investors seeking stable returns.
To see Spark’s full report on CVM stock, click here.
More about Cel-Sci
YTD Price Performance: -28.25%
Average Trading Volume: 799,212
Technical Sentiment Signal: Sell
Current Market Cap: $58.73M